Navigation Links
Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
Date:10/1/2007

Delsym is the only FDA-approved 12-hour non-prescription liquid cough

suppressant

CHESTER, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Adams Respiratory Therapeutics, Inc. (Nasdaq: ARxT) today announced that the Food and Drug Administration (FDA) approved its supplemental New Drug Application for a grape-flavored formulation of Delsym Extended-Release Suspension on Friday, Sept. 28, 2007. The Company will immediately commence distribution of grape Delsym product to its trade customers.

Delsym is the first and only over-the-counter (OTC) liquid that controls cough for a full 12 hours with a single dose, providing all day or all night cough suppression with each dose. Delsym's patented single-ingredient formula delivers great tasting medicine in orange and now new grape flavors for both children and adults.

About Adams Respiratory Therapeutics, Inc.

Adams is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.


'/>"/>
SOURCE Adams Respiratory Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Passive smoking affects respiratory system
2. Occupational exposurer aises respiratory symptoms
3. Severe Acute respiratory Syndrome (SARS)
4. WHO Travel Advice to prevent spread of "Severe Acute Respiratory Syndrome (SARS)
5. Good News for New Borns With Hypoxic Respiratory Failure
6. Understanding The Link Between Hormone Replacement and Respiratory Disease
7. Hand sanitizers may reduce respiratory and gastrointestinal infections at home
8. Antibiotics for acute uncomplicated lower respiratory tract infection
9. Handwashing prevents diarrhea and acute lower respiratory infections
10. New Virus Held Responsible For Respiratory Infection In Children
11. Second Hand Exposure To Smoke In Childhood Can Cause Respiratory Problems Later
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Ron ... an option to senior, upper-level executives speaking at a business luncheon today, "It ... high-level executive is an asset to be fully realized and activated by the ...
(Date:9/25/2017)... ... September 25, 2017 , ... “Renew Refresh Restore Reward”: is a ... Reward” is the creation of published author, Deborah Freeman, cofounded the Free Spirit Bible ... we returned to our cars, my sister-in-law invited us to come over before the ...
(Date:9/25/2017)... September 25, 2017 - Orlando, FL, Microsoft Ignite Conference (PRWEB) , ... ... ... Hosts, Inc . announced today that they have teamed up to deliver Netmail’s Hadron ... on-demand service from a HIPAA/HITRUST compliant Azure Cloud. Netmail will be demo-ing their Hadron ...
(Date:9/25/2017)... ... ... Ash Borers kill Ash trees in as little as 1-3 years. The signs ... by Rob Nagy, ISA Certified Arborist at Giroud Tree and Lawn, shows a street in ... signs of decline from Emerald Ash Borers, two Ash trees continue to thrive. ...
(Date:9/24/2017)... & Caicos Islands, BWI (PRWEB) , ... September 25, 2017 , ... ... to announce the resort is re-opening on October 1st. And, throughout the month ... three bedroom oceanfront rentals. , Hurricane Irma and Maria have passed and damage ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
Breaking Medicine Technology: